Lil Miedzinski

Summary

Affiliation: University of Alberta
Country: Canada

Publications

  1. ncbi Echinococcal disease in Alberta, Canada: more than a calcified opacity
    Ali Somily
    Department of Pathology, University of Alberta, Edmonton AB, Canada
    BMC Infect Dis 5:34. 2005
  2. ncbi Community-acquired pneumonia: new facets of an old disease--Hantavirus pulmonary syndrome
    Lil Miedzinski
    Department of Medicine, School of Medicine, E2, 440 112th Street, University of Alberta, Edmonton, Alberta T6G 2B7, Canada
    Respir Care Clin N Am 11:45-58. 2005
  3. ncbi Placebo-controlled, double-blind trial of intravenous ribavirin for the treatment of hantavirus cardiopulmonary syndrome in North America
    Gregory J Mertz
    Internal Medicine, University of New Mexico, Albuquerque, New Mexico 87131 0001, USA
    Clin Infect Dis 39:1307-13. 2004

Collaborators

Detail Information

Publications3

  1. ncbi Echinococcal disease in Alberta, Canada: more than a calcified opacity
    Ali Somily
    Department of Pathology, University of Alberta, Edmonton AB, Canada
    BMC Infect Dis 5:34. 2005
    ..granulosus. There are limited descriptions of the clinical course and outcome of Canadian patients with ED in the modern era...
  2. ncbi Community-acquired pneumonia: new facets of an old disease--Hantavirus pulmonary syndrome
    Lil Miedzinski
    Department of Medicine, School of Medicine, E2, 440 112th Street, University of Alberta, Edmonton, Alberta T6G 2B7, Canada
    Respir Care Clin N Am 11:45-58. 2005
    ..The declining mortality rates seen over the past decade may be a consequence of improved medical management or better recognition of cases, including those less severe than originally described...
  3. ncbi Placebo-controlled, double-blind trial of intravenous ribavirin for the treatment of hantavirus cardiopulmonary syndrome in North America
    Gregory J Mertz
    Internal Medicine, University of New Mexico, Albuquerque, New Mexico 87131 0001, USA
    Clin Infect Dis 39:1307-13. 2004
    ..BACKGROUND. Ribavirin is active in vitro against hantaviruses, but the findings of an open trial of the use of intravenous ribavirin for the treatment of hantavirus cardiopulmonary syndrome (HCPS) were inconclusive...